SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Procept (PRCT): 50% rise on high volume. Why?
PRCT 30.67-2.1%1:41 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Douglas who wrote (149)4/26/1997 1:45:00 PM
From: Douglas   of 455
 
The Terrence Higgins Trust in England has a two page briefing on microbicides (Dec. 96). The briefing explains what a microbicide is, why is it important to develop an effective microbicide,what new products are currently being researched (did you know there are thirty-five products undergoing trials), and what you can do and where to find out more (talks about St Mary's Hospital, London recruiting volunteers).

If interested go to: tht.org.uk

In the paragraph discussing new products does anyone know what company is developing "dextrin sulphate"? My search of the internet revealed nothing. Anytime dextrin sulphate is mentioned there is no mention of the responsible company. There is a press release from the United Kingdom dated 3 April 1997. The title is "Anti-HIV Gel Found Safe and Well Tolerated Intravaginally". I don't think there talking about Procept. Maybe it's government research. If interested go to (g-97-04-03.html) at:

hivpositive.com

Another company, BioQuest of Houston, Texas is mentioned as having received a US patent for a compound called S4S, a prophylactic preparation for HIV infection. If interested go to (m-97-03-07.html) at:

hivpositive.com

The 1996 UNAIDS press release for Advantage 24 is at:

us.unaids.org
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext